NeoGenomics (NEO) Adds Rachel A. Stahler and Michael A. Kelly to Board
- S&P 500 ends higher as markets weigh rising yields, upbeat corporate results
- Meta Platforms reports softer Q2 revenue guidance on plans to boost spending on AI
- IBM (IBM) announces mixed Q1 results, HashiCorp acquisition; shares down
- Equities mixed as investors eye earnings; yen on intervention watch
- ServiceNow (NOW) stock falls as refreshed subscription outlook trails estimates
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Hasbro (HAS) brand strength sees earnings top expectations
- IBM (IBM) announces mixed Q1 results, HashiCorp acquisition; shares down
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
NeoGenomics Announces Board Appointments
July 20, 2020 7:01 AM EDTFT MYERS, FL / ACCESSWIRE / July 20, 2020 / NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today changes in the composition and certain roles of its Board of Directors.
Rachel A. Stahler joined our Board of Directors on May 28, 2020 and will serve as a member of the Audit Committee and the Nominating and Governance Committee. Ms. Stahler is the Chief Information Officer at Organon & Co., Merck & Co. Inc.'s intended spinoff of its women's health, legacy brands and biosimilars businesses. Ms. Stahler has nearly two decades of global technology experience in the... More